Inactive Instrument

Actelion Ltd Stock Swiss Exchange

Stocks

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
18/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.33%	+1.37%	+63.66%	+123.67%	55.63B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.52%	+88.67%	52.25B
BIONTECH SE	+1.36%	+0.36%	-14.52%	-14.67%	23.07B
INSMED INCORPORATED	-1.04%	+7.91%	+3.91%	+413.05%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.20%	+31.37%	-12.59%	17.32B
GENMAB A/S	-1.10%	+4.00%	+29.97%	-32.75%	15.94B
EXELIXIS, INC.	+2.89%	+5.51%	+25.42%	+188.41%	13.77B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+134.32%	+282.61%	13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+0.53%	+27.83%	-	12.43B
Average	+0.12%	+4.78%	+42.39%	+129.55%	25.14B
Weighted average by Cap.	+0.26%	+5.13%	+48.50%	+121.99%

Employees

Sector